# Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

> **NCT03722108** · PHASE1,PHASE2 · TERMINATED · sponsor: **UNICANCER** · enrollment: 89 (actual)

## Conditions studied

- Adenocarcinoma of the Stomach
- Adenocarcinoma of the Gastroesophageal Junction

## Interventions

- **COMBINATION_PRODUCT:** Regorafenib and Irinotecan
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03722108
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-07
- **Primary completion:** 2022-05-19
- **Final completion:** 2022-05-19
- **Target enrollment:** 89 (ACTUAL)
- **Why stopped:** Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate efficacy and safety analysis
- **Last updated:** 2023-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03722108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03722108, "Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03722108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*